The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


DuoPlavin

75/75 mg/mg Film-coated tablet

Sanofi-Aventis GroupeEU/1/10/619/001

Main Information

Trade NameDuoPlavin
Active SubstancesClopidogrel hydrogen sulphate
Acetylsalicylic acid
Strength75/75 mg/mg
Dosage FormFilm-coated tablet
Licence HolderSanofi-Aventis Groupe
Licence NumberEU/1/10/619/001

Group Information

ATC CodeB01AC Platelet aggregation inhibitors excl. heparin
B01AC30 combinations

Status

Authorised/WithdrawnWithdrawn
Withdrawn Date21/01/2020
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back